[Nephrotic syndrome disclosing AIDS].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to B Viron.
Explore the source record for details and available documents.
The effects of renal revascularization on blood pressure and renal function were evaluated in 8 hypertensive patients with renal impairment and renal artery stenosis in both kidneys (6 cases) or in a solitary kidney (2 cases). Mean age was 66 +/- 7 years. The mean duration of arterial hypertension was 13 +/- 8 years. In spite of treatment with 3 antihypertensive drugs (or more in 5 cases) blood pressure values ranged from 170-90 to 260-150 mmHg. Adding captopril (in 3 cases) or minoxidil (in 1 case) resulted in control of hypertension in 1 patient and further deterioration of renal function in 2. Two patients underwent surgery after failure of percutaneous transluminal angioplasty. There were 6 revascularizations and 2 nephrectomies with contralateral revascularization. One patient died post-operatively. In the remaining 7 patients, the hypertension was controlled with one or two drugs and the renal function remained stable or improved over a mean follow-up period of 2 years. We consider that these results warrant radiological exploration in all patients, even old, with renal impairment and drug-resistant hypertension. Renal revascularization must be performed as early as possible in view of the rapid degradation of renal function under medical treatment in these patients.
In HIV-infected patients with end-stage renal failure maintenance dialysis raises multiple problems, the most important of these being the quality and duration of life in these patients and the risk of contaminating other HIV negative patients under dialysis and/or members of the medical-nursing staff. In this study the results obtained in 14 patients treated in one single centre over a 5-year period are analyzed. Nine patients (group I) had end-stage renal failure consecutive to HIV-associated nephropathy: 5 died after 2 to 30 months (mean 9.2 +/- 5.2) of dialysis, while 4 patients were alive at the end of the study with a mean follow-up of 23.8 +/- 8.8 months (5 to 50). Five patients (group II) had end-stage renal failure consecutive to a nephropathy unrelated to HIV: only 1 female patient died 29 months after she was found to be seropositive; the remaining 4 patients were alive at the end of the study with a mean 47.5 +/- 5.5 months (33 to 58) of follow-up. Ten patients were found to have a less than 8 g/dl Hb anaemia which was corrected in the 4 patients who received recombinant human erythropoietin. Out of the 9 patients treated with zidovudine (300 mg/day) 6 had haematological side-effects. Throughout this study, there was no contamination of HIV negative patients or members of the medical-nursing staff. In these 2 groups, the survival of HIV positive patients dialysed for chronic renal failure seems to have been conditioned by the stage of HIV infection at the time when maintenance dialysis was instituted.